Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
Aphranel’s CaHA filler has secured EU MDR certification. Find out what this means for regenerative aesthetics and Europe’s filler market.
Why Tempus AI’s Lens upgrade matters for precision oncology drug development
Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.
Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?
Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.
Can MD Hyperbaric turn medical-grade HBOT into a mainstream recovery clinic model?
HBOT demand is rising beyond hospitals. MD Hyperbaric’s clinic expansion tests whether recovery care can scale without losing clinical rigor.
What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology
Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.
FDA breakthrough status gives Coredio’s AI heart failure platform a faster regulatory path
Coredio’s AI heart failure platform may bring hemodynamic insight into home care. See why FDA breakthrough status matters now.
Why DELFI Diagnostics’ New York approval could shake up the lung cancer screening market
DELFI Diagnostics can now offer FirstLook Lung in all 50 states. Find out what this means for blood-based cancer screening.
Why the Radoff-JEC bid for Seer is bigger than a small-cap biotech takeover fight
Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.
Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery
DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.